Drugmakers to raise US prices on over 250 medicines
Recent market volatility has created an attractive entry point for both stocks heading into 2025. Their dividend yields now ...
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, ...
Hosted on MSN11h
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong ...
The U.S. already has the world's highest prescription drug prices, and these annual increases will push up costs for COVID and cancer treatment, among many medications.
Pre-tax profits at the main Irish unit of pharma giant Bristol Myers Squibb last year declined by 42% to $3.97 billion (€3.82 ...
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback